News & Updates

Show Multimedia Only

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026 by

In the phase III EPIK-B5 study, adding alpelisib, an α-specific PI3K inhibitor, to fulvestrant improves progression-free survival (PFS) in men and postmenopausal women with HR+, HER2− advanced breast cancer (ABC) harbouring a PIK3CA mutation who have progressed on or after treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).

EPIK-B5 supports alpelisib plus fulvestrant for HR+, HER2– ABC

15 Jan 2026

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

15 Jan 2026

Risk-reducing bilateral mastectomy in patients with the BRCA pathogenic variant appears to be associated with lower overall and breast-cancer specific mortality, according to a meta-analysis.

Risk-reducing bilateral mastectomy confers survival benefit in BRCA carriers

15 Jan 2026

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

In the treatment of patients with advanced soft-tissue sarcoma, combining anlotinib with anthracyclines and ifosfamide in the first-line setting followed by anlotinib maintenance has demonstrated promising efficacy, with acceptable toxicities, in a phase II study.

Frontline anlotinib-containing regimen shows promise in advanced soft-tissue sarcoma

14 Jan 2026

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026 by

Metastasis-directed stereotactic body radiotherapy (SBRT) alone can delay the need for systemic therapy in some patients with oligometastatic cancer, with low risks of treatment-related adverse events, according to a meta-analysis.

Metastasis-directed SBRT alone may be enough for patients with oligometastatic disease

13 Jan 2026

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026 by

Patient fatigue reported before the initiation of cancer treatment appears to be associated with an increased risk of subsequent treatment-related adverse events, according to new research.

Patient fatigue flags risk of toxicity from cancer treatment

10 Jan 2026

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

T-DXd plus RT shows promise in management of metastatic breast cancer

09 Jan 2026

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026 by

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Ropeginterferon alfa-2b fares well for ET in ROP-ET trial

09 Jan 2026

OAB symptoms may increase in breast cancer patients undergoing chemotherapy

08 Jan 2026

Symptoms of overactive bladder (OAC) tend to rise among women receiving both trastuzumab and pertuzumab for HER2-positive positive breast cancer during their treatment, reports a study.